Charles River Laboratories International, Inc. has announced a significant update regarding its ownership structure, as disclosed in a recent filing. FMR LLC, a prominent investment management firm, now holds 12.4% of the company's common stock. This change is noteworthy as it reflects FMR LLC's growing influence in the commercial physical and biological research sector.

The filing, made on November 5, 2026, indicates that FMR LLC beneficially owns approximately 5,922,755 shares of Charles River Laboratories. The filing also specifies that Abigail P. Johnson, the Chairman and CEO of FMR LLC, has a substantial stake in the company.

Background

Founded in 1947, Charles River Laboratories International, Inc. (NYSE: CRL) is a leading provider of essential products and services to the pharmaceutical and biotechnology industries. The company specializes in preclinical and clinical laboratory services for the evaluation of new drugs and therapies. With a focus on innovation and quality, Charles River plays a crucial role in advancing the drug development process.

According to its recent filings, Charles River operates within the SIC classification of 8731, which encompasses services related to commercial physical and biological research. The company has consistently demonstrated its commitment to supporting the life sciences sector through its comprehensive range of services.

What the Filing Says

The Schedule 13G/A filing reveals that FMR LLC has increased its stake in Charles River Laboratories to 12.4%. The filing states, "This filing reflects the securities beneficially owned, or that may be deemed to be beneficially owned, by FMR LLC, certain of its subsidiaries and affiliates, and other companies." This indicates a strategic investment approach by FMR LLC, which could lead to greater involvement in the company's governance.

Impact

This updated ownership structure may have several implications for Charles River Laboratories and its stakeholders. With FMR LLC holding a significant percentage of shares, it may influence key decisions and strategies moving forward. Institutional investors like FMR LLC often advocate for corporate governance changes that align with their investment goals, potentially affecting how the company operates.

Additionally, this move may signal confidence in Charles River's future prospects, which could attract further investment from other institutional players in the commercial physical and biological research sector.

What's Next

The filing does not specify what actions may follow this increase in ownership by FMR LLC. However, it highlights the ongoing importance of institutional investors in shaping the direction of companies like Charles River Laboratories. Stakeholders will likely be watching closely for any developments or strategic initiatives that may arise as a result of this significant investment.